June 30, 2017 07:37 AM EDT

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program

John Carroll

Editor & Founder

A Kentucky biotech says they’re laying the foundation for a pivotal program for their C3 inhibition therapy, which execs believe can replace Soliris in treating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Far from the big hubs, Apel­lis is steer­ing its ri­val to Alex­ion's Soliris in­to a PhI­II pro­gram

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program